FibroBiologics reports Q3 2026 net loss of $4 million
FBLG•FibroBiologics reported a third-quarter 2026 net loss of approximately $4 million and had approximately $1.2 million in cash and cash equivalents at September 30, followed by about $1 million in cash infusions.
1. Quarterly results and cash
Research and development expenses fell 25% year over year to approximately $2.1 million, while general and administrative costs declined 9% to $2 million. FibroBiologics said initial CYWC628 trial safety data are expected in mid-December 2026, with interim efficacy results anticipated in February 2027.




